Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × nirogacestat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 9 Desmoid Tumors 5 Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Leukemia 1 Hematologic Diseases 1 HIV Infections 1 Granulosa cell tumor of the ovary 1 Corneal Diseases 1 Breast Neoplasms 1 Breast Cancer Metastatic 1 Blood Protein Disorders 1 Advanced Solid Tumors 1 AIDS-related Kaposi sarcoma 1

Interventions

Trastuzumab 493 Paclitaxel 463 Cyclophosphamide 459 Docetaxel 405 Capecitabine 336 Letrozole 288 Fulvestrant 253 Doxorubicin 238 Carboplatin 222 Tamoxifen 211 Anastrozole 177 Radiotherapy 173 exemestane 171 Epirubicin 169 Bevacizumab 161 Lapatinib 141 Vinorelbine 139 Gemcitabine 136 pembrolizumab 135 pertuzumab 134 palbociclib 119 Exercise 107 Fluorouracil 100 Albumin-Bound Paclitaxel 99 Magnetic Resonance Spectroscopy 98 eribulin 94 130-nm albumin-bound paclitaxel 86 Everolimus 84 Cisplatin 79 abemaciclib 75

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02338531 2016-04-29

RHEA

Jules Bordet Institute

Phase 2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡